iCanWork: A Randomized Controlled Trial

McGill University (Other)
Overall Status
Not yet recruiting
CT.gov ID

Study Details

Study Description

Brief Summary

The aim of this study is to evaluate the effectiveness of the iCanWork intervention in assisting cancer survivors (CS) to return to work (RTW) and its impact on their health-related quality of life (QoL), health service utilization, RTW readiness, time to RTW, and work capacity.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: iCanWork Intervention

Detailed Description

The iCanWork intervention comprises several elements related to health and work, taken from the latest reviews that recommend a remote and individual intervention, led by a vocational rehabilitation counsellor (VRC), experts in assisting RTW for CS. The intervention includes 6 sessions with a VRC and 1-4 sessions with an occupational therapist (OT). A total of 270 CS will be recruited into 2 groups (intervention or control). The duration of this study is 24 months. Study participants will complete electronic questionnaires measuring study variables at baseline before randomization and at 6-month, 12-month, 18-month, and 24-month follow-ups.

Study Design

Study Type:
Anticipated Enrollment :
270 participants
Intervention Model:
Parallel Assignment
Double (Participant, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Effects of the iCanWork Intervention to Improve Cancer Survivors' Experience With Return to Work: A Randomized Controlled Trial (RCT)
Anticipated Study Start Date :
Apr 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2025
Anticipated Study Completion Date :
Sep 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: iCanWork Intervention

iCanWork includes 6 1-hour sessions with a VRC and 1 to 4 1-hour sessions with an OT. In the positive event that a participant has returned to work during the study, three of the six VRC sessions are reserved to support the participants in their transition to the workplace.

Behavioral: iCanWork Intervention
Participants will receive RTW support from the VRC and OT.

No Intervention: Control

Participants randomized to the control group will receive their usual care and will be referred to the Cancer Work website for educational resources related to RTW. If they contact the team with RTW-related questions, they will be referred to their care teams.

Outcome Measures

Primary Outcome Measures

  1. Change from baseline return to work status in the course of the 24-month study [baseline, 6 months, 12 months, 18 months, 24 months]

    binary variable (Yes/No)

Secondary Outcome Measures

  1. Change from baseline health related quality of life in the course of the 24-month study [baseline, 6 months, 12 months, 18 months, 24 months]

    The Patient Reported Outcome Information System (PROMIS) - Preference scale is a valid, 31-item tool to measure 7 domains of quality of life (i.e., cognition, depression, fatigue, pain, physical function, sleep disturbance, and ability to participate in social roles and activities). Each of these items is measured on five levels (e.g., "never", "rarely", "sometimes", "often", "always" or "not at all", "a little bit", "somewhat", "quite a bit", and "very much"). The responses (1 to 5 on a Likert scale) were transformed into PROMIS theta scores (mean = 0 ± SD = 1) or T-Scores (mean = 50 ± SD = 10). For cognition, physical function, and ability to participate in social roles and activities, higher T-Scores (thetas) indicate more desirable outcomes. For depression, fatigue, pain, and sleep disturbance, lower T-Scores (thetas) indicate more desirable outcomes.

  2. Change from baseline readiness to return to work in the course of the 24-month study [baseline, 6 months, 12 months, 18 months, 24 months]

    The Readiness for Return-To-Work Scale is a validated 22-item measure of the readiness to return to work stages and consists of two scales; Scale A contains 13 items for individuals who are not working and Scale B includes 9 items for individuals who are working either part or full time. Each item is scored using a 5 point scale (1 = strongly disagree, 5 = strongly agree) representing a specific readiness stage: Pre-contemplation; Contemplation; Prepared for Action-Self-evaluative; and Prepared for Action-Behavioural for those not back at work and Uncertain Maintenance or Proactive Maintenance for those who are currently working. The scale provides a final score for each readiness stage by taking the mean of the items that create that factor. Higher scores associated with a readiness stage indicate higher level of beliefs associated with that stage.

  3. Change from baseline work capacity in the course of the 24-month study [baseline, 6 months, 12 months, 18 months, 24 months]

    Work capacity will be measured with the 7-item validated Work Capacity Index which measures seven domains related to the level of work capacity namely: 1) current work capacity compared to pre-cancer work capacity; 2) current work capacity compared to job demands; 3) number of physician-diagnosed health problems; 4) work disability due to illnesses; 5) days of absenteeism since stopping work due to cancer; 6) prognosis of anticipated work capacity for the next two years; and 7) psychological resources. The score of the 7 domains is summed ranging from 7 to 49 with a higher score indicating a greater capacity for work.

Eligibility Criteria


Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Inclusion Criteria:
  • diagnosed with cancer (all types) treated with curative intent and of working age (between 18 and 65 at the time of diagnosis)

  • gainfully employed at the time of diagnosis (full or part-time, including students)

  • still on sick leave, including long-term disability leave, but for less than 2 years

  • has not started to return to work, since stopping due to cancer

  • can read and understand English or French

  • reside in Canada.

Exclusion Criteria:
  • If the cancer survivor's physicians consider returning to work unwise, such as due to a metastatic cancer diagnosis

Contacts and Locations


Site City State Country Postal Code
1 McGill University Montréal Quebec Canada H3A 0G4

Sponsors and Collaborators

  • McGill University


None specified.

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
Christine Maheu, Associate Professor, McGill University
ClinicalTrials.gov Identifier:
Other Study ID Numbers:
  • iCanWork_CIHR
First Posted:
Sep 21, 2022
Last Update Posted:
Sep 26, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Keywords provided by Christine Maheu, Associate Professor, McGill University

Study Results

No Results Posted as of Sep 26, 2022